STAT stories you may have missed 

Read Adam Feuerstein’s latest column on biotech in the time of coronavirus. Complete with dog pics.

AstraZeneca halted a study of its lung cancer drug Tagrisso, citing overwhelming benefit.

The Trump administration proposed modest efforts to support generics and biosimilars. Both were lambasted by industry.

How will Covid-19 impact biotech in the months ahead? Read STAT’s interview with one biotech analyst. 

Why you shouldn’t celebrate just yet over venture-backed biotech’s record breaking quarter. 

Is the cost of naloxone a barrier to its use? One study says yes. 

A big biotech deal: Roche partners with Arrakis Therapeutics.